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Abstract
Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women, and there has been no
substantial decrease in the death rates due to EOC in the last three decades. Thus, basic knowledge regarding
ovarian tumor cell biology is urgently needed to allow the development of innovative treatments for EOC.
Traditionally, EOC has not been considered an immunogenic tumor, but there is evidence of an immune response
to EOC in patients. Clinical data demonstrate that an antitumor immune response and immune evasion
mechanisms are correlated with a better and lower survival, respectively, providing evidence for the immunoediting
hypothesis in EOC. This review focuses on the immune response and immune suppression in EOC. The
immunological roles of chemotherapy and surgery in EOC are also described. Finally, we detail pilot data
supporting the efficiency of immunotherapy in the treatment of EOC and the emerging concept that
immunomodulation aimed at counteracting the immunosuppressive microenvironment must be associated with
immunotherapy strategies.
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Introduction
Epithelial ovarian cancer (EOC) is the fifth most common
cancer among women and the fourth most common cause
of cancer-related death among women in developing
countries [1]. The prognosis is poor, with a 5-year survival
rate of 30%. The majority of patients relapse within 16–
18 months following the end of treatment and die from
the disease despite response to first-line therapy consisting
of debulking surgery and chemotherapy [2,3]. 15% of
patients die within the first year. No substantial decrease
in the death rate occurred in the last three decades. Thus,
there is an urgent need for basic knowledge of ovarian
tumor biology for the development of innovative EOC
treatments.
Unlike melanoma or renal and hematologic tumor
diseases, EOC is not considered to be immunogenic.
However, there is evidence of an immune response
against EOC in patients [4]. Experimental data show that
the inflammatory microenvironment of EOC prevents
the maturation of myeloid cells, favors regulatory cell
development and restrains the cytotoxic activity of ef-
fector lymphocytes, leading the tumor to escape from
the immune system and triggering cancer progression
[5]. Treatments such as chemotherapy with paclitaxel/
carboplatin and debulking surgery are traditionally con-
sidered to negatively impact the immune system during
EOC [6]. However, recent data challenge this concept
and highlight the major role of immune response in
EOC. Indeed, aforementioned treatments were shown to
modulate the host response and to decrease the im-
munosuppression [7,8]. Thus, immunotherapies aimed
at increasing the host immune response or decreasing
immunosuppression were tested in preclinical and clinical
studies and are emerging as potential strategies to enhance
classical EOC treatments.
In this article, we present an overview of the current
understanding of the immune response and immune
suppression in EOC. The immunological role of che-
motherapy and surgery is highlighted, and pilot data
supporting the efficiency of immunotherapy in EOC
treatment are reviewed.
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Evidence of an immune response in EOC
EOC expresses or overexpresses tumor-associated anti-
gens (TAA), i.e. antigens (Ag) acquired by tumor cells in
the process of neoplastic transformation that can elicit a
specific T-cell immune response by the host. In 1993,
EOC ascites were found to contain CD8+ T-cells capable
of recognizing HER2/neu-positive tumor cells [9]. 5 to
66% of EOC exhibit this EGFR-related glycoprotein that
activates signaling pathways involved in cellular prolifer-
ation [10,11]. Many other TAA were described in EOC,
such as folate receptor(FR)-α [12], epithelial cell adhe-
sion molecule (EpCAM) [13], human epididymis protein
4 [14], p53 [15], mucin-like MUC16 (CA125) and
MUC1 (CA15.3) [16] and TAA of the cancer-testis
group [17,18]. Tumor-reactive T-cells and antibodies
(Ab) directed against TAA were detected in the periph-
eral blood of patients with advanced-stage disease at the
time of diagnosis [15,19], and tumor-reactive T-cells
were isolated from tumors or ascites [20].
Furthermore, there is clinical evidence for the role of
immunosurveillance against EOC. The detection of
intraepithelial tumor-infiltrating lymphocytes (TIL)
correlates with clinical outcome. Zhang et al. detected
CD3+ TIL in 102/186 frozen specimens from patients
with stage III/IV EOC [21]. The five-year progression-
free survival rates were 31.0% and 8.7% for patients
with and without TIL, respectively. The presence of
TIL correlated with progression-free survival in multi-
variate analysis (p < 0.001) [21]. Recently, other studies
confirmed that the CD3+ TIL count is a significant
prognosis factor in EOC (Table 1) [22-32]. High frequen-
cies and activity levels of immune effector cells such as
CD8+ T-cells, Natural Killer(NK)-cells and Vγ9Vδ2T-cells
are correlated with positive clinical outcomes for EOC pa-
tients [33,34]. Thelper(Th)-17 cells, a recently discovered
T-lymphocyte subset, were found in proportionally
higher number in EOC microenvironment in compari-
son with other immune cells [35,36]. In EOC patients,
Th17 levels in the tumor correlated positively with
Th1-cells, cytotoxic CD8+ T-cells and NK-cells and
Th17 levels in ascites correlated positively with patient
survival [35]. Intriguingly, Th17 were reported to pro-
mote either tumor cell growth or antitumor response
and their role in cancer development is currently under
Table 1 Clinical arguments for the immunoediting hypothesis in epithelial ovarian carcinoma
Authors Year Findings
Spontaneous anti-tumor response
Zhang L et al. [21] 2003 Association between intraepithelial T-cell infiltration (TIL CD3+) and patient survival
Raspollini NR et al. [22] 2005 Association between intraepithelial T-cell infiltration (TIL CD3+) and patient survival (plus chemotherapeutic
response)
Sato E et al. [23] 2005 Association between intraepithelial T-cell infiltration (TIL CD8+) and patient survival
Hamanishi J et al. [24] 2007 Association between intraepithelial T-cell infiltration (TIL CD3+) and patient survival
Clarke B et al. [25] 2008 Association between intraepithelial T-cell infiltration (TIL CD8+) and patient survival (only for high grade serous
EOC, but not for endometrioïd or mucinous EOC)
Shah CA et al. [26] 2008 Association between intraepithelial T-cell infiltration (TIL CD8+) and optimal debulking surgery
Tomsova M et al. [27] 2008 Association between intraepithelial T-cell infiltration (TIL CD3+) and patient survival
Callahan MJ et al. [38] 2008 Association between intraepithelial T-cell infiltration (TIL CD8+) and patient survival
Han LY et al. [28] 2008 Association between intraepithelial T-cell infiltration (TIL CD3+ and CD8+) and patient survival
Stumpf M et al. [29] 2009 Association between intraepithelial T-cell infiltration (TIL CD3+ and CD8+) and patient survival
Leffers N et al. [30,39] 2009 Association between intraepithelial T-cell infiltration (TIL CD8+) and patient survival
Milne K et al. [31] 2009 Association between intraepithelial T-cell infiltration (TIL CD3+ and CD8+) and patient survival
Adams SF et al. [32] 2009 Association between intraepithelial T-cell infiltration (TIL CD3+ and CD8+) and patient survival
Kryczek I et al. [35] 2009 Association between intraepithelial T-cell infiltration (TIL CD4+ with IL-17 secretion) and patient survival
Tumor immune evasion
Curiel TJ et al. [36] 2004 Inverse association between survival and intratumoral regulatory T cells (CD4+CD25+FoxP3+)
Wolf D et al. [40] 2005 Inverse association between survival and intratumoral regulatory T cells (FoxP3+)
Dong HP et al. [41] 2006 Inverse association between survival and intratumoral NK (CD3- CD16+) or B cells (CD19+)
Kryczek I et al. [42] 2007 Inverse association between survival and intratumoral B7-H4+ macrophage or regulatory T cells (FoxP3+)
Hamanishi J et al. [24] 2007 PD-L1 expression by tumor predicts low T-cell infiltration
Buckanovitch RJ et al. [43] 2008 Endothelin B receptor (ETBR) expression restricts T-cell infiltration and predicts poor survival
Labidi-Galy SI [44,45] 2011 Inverse association between survival and intratumoral pDC (CD4+, CD123+, BDCA2+)
PD-1: programmed cell death 1; PD-L1: PD-1 ligand 1; ETBR: endothelin B receptor; pDC: plasmacytoïd dendritic cells.
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debate [37]. Finally, in addition to TIL, the number of per-
ipheral blood immune cells, e.g. NK-cells, is also corre-
lated with survival in EOC [33]. All these results support
the existence of immunosurveillance in EOC (Figure 1).
Immune escape in EOC
The tumor immunosurveillance concept was postulated
in the 1960s by Burnet and Thomas, who proposed that
the immune system patrols the body to recognize and
destroy host cells that become cancerous and that the
immune system is responsible for preventing cancer de-
velopment [46]. This concept was then replaced by the
cancer-immunoediting hypothesis, in which the immune
system shapes tumor immunogenicity with three succes-
sive phases: elimination, equilibrium and escape [47].
Immune escape in EOC involves several mechanisms
that implicate tumor, immune and stromal cells. Ovarian
tumor cells escape immune recognition by downregulating
surface molecules involved in Ag presentation, such as β2-
microglobulin and Major Histocompatibility Complex
(MHC) [28]. Similarly, the downregulation of MHC class
I-related chain A (MICA) expression impedes the detec-
tion of tumor cells by innate cytotoxic effector cells
through the engagement of the NKG2D-activating recep-
tor [48,49]. Additionally, ovarian tumor cells overexpress
molecules that counteract the cytotoxic activities of im-
mune cells: CA125 binds the NK-cell inhibitory receptor
(KIR) siglec-9, thereby protecting themselves from NK-
mediated lysis [50,51]; the macrophage migration in-
hibitory factor (MIF) downregulates NKG2D-activating
receptor expression on NK-cells [52]. Furthermore, en-
gagement of programmed death-1 (PD-1) on CD8+ T-cells
by programmed death-1 ligand-1 (PD-L1) expressed by
ovarian tumor cells impairs the effector functions of
these lymphocytes [24,53]. Wide panel of cancers, includ-
ing EOC, were also shown to express indolamine-2,3-
Figure 1 Immune network in EOC. EOC is immunogenic and expresses tumor-associated antigens such as HER2/neu, CA125 and Folate
Receptor α. Various immune effectors such as CD8+ T-cells, NK-cells and Vγ9Vδ2T-cells can attack tumor cells, but immunosuppressive crosstalk
counteracts the functions of these effector cells. Treg, tolerogenic DC, MDSC, B7-H4+ TAM and non-immune cells such as mesenchymal stem
cells and tumor cells themselves halt antitumor activities through cell-cell contacts (CA125/siglec pathway, PD-1 and CTLA-4 immunosuppressive
checkpoints) or the production of soluble factors (IL-10, TGF-β, PGE2, MIF, arginase-1, and IDO).
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dioxygenase (IDO), an intracellular enzyme that catalyzes
the rate-limiting step in the metabolism of the essential
amino acid tryptophan [54,55]. IDO is a beneficial host
mechanism regulating immune responses in various
contexts such as pregnancy, transplantation or infec-
tion. It was proposed to elicit feedback process, there-
fore preventing deleterious consequences of excessive
immune responses. However, this endogenous mechanism
is hijacked by tumors to establish immunotolerance to
tumor antigens [56,57].
Immune cells also play a major role in the immune
escape in EOC [58]. The EOC-specific recruitment of
CD4+CD25+FoxP3+ regulatory T-cells (Treg), tolerogenic
dendritic cells (DC), B7-H4+ tumor-associated macro-
phages (TAM) and myeloid-derived suppressor cells
(MDSC) fosters immune privilege and predicts reduced
survival in EOC (Table 1) [23,36,44,59-62]. Accumulation
of Treg is now well documented in various tumors includ-
ing EOC [23,36,38-41]. CCR4 chemokine receptor expres-
sion confers to Treg higher capacity than effector T-cells
to infiltrate the tumor in response to CCL22 chemokine
produced by either tumor cells or TAM [36]. In addition,
Treg could originate from in situ expansion. In that set-
ting, ICOS-ligand costimulation provided by plasmacytoid
DC (pDC) was recently highlighted as a prominent signal
triggering in situ Treg expansion in some tumors, in-
cluding EOC [63,64]. At last, de novo conversion of
FoxP3- cells into Treg was shown to occur in the tumor
as a consequence of TGF-β stimulation or IDO induc-
tion [65,66]. Treg mainly mediate immunosuppression
through cell-cell contacts with DC or effector cells or
by the secretion of immunosuppressive cytokines, in-
cluding IL-10, IL-35 and TGF-β [67]. Treg notably con-
tribute to DC tolerization, thereby further reducing the
effector T-cell activation and proliferation. Interestingly,
association of tumor regulatory T-cells with high hazard
ratio for death and decreased survival times is currently
well documented in EOC [23,36,42]. Besides Treg, DC
are instrumental in establishing immunosupression in
cancer. While DC were initially recognized as the pri-
mary orchestrators of the immune response, their role
in the immunotolerance is now well established [68].
Importantly, both conventional myeloid DC (cDC) and
pDC are characterized by high plasticity [69]. Conse-
quently, their immune properties could be modulated by
environmental stimuli and tumors may benefit from this
Achille’s heel to induce DC tolerization and to reduce the
adaptive immunity to tumor antigens. Accordingly, studies
showed that the EOC microenvironment converts DC
toward an immunosuppressive phenotype [70]. In a
mouse model of EOC, Scarlett et al. showed that the
DC phenotype controls EOC progression. Indeed, the
switch of infiltrating-DC from activating to regulatory
phenotype coincides with rapid tumor progression to
terminal disease [62]. The role of pDC in EOC immunity
was proposed by Zou et al. that evidenced the recruitment
of pDC in response to stromal-derived factor-1 (SDF-1/
CXCL-12) secretion by EOC [71]. The accumulation of
pDC within the EOC was shown to be associated with
shorter progression-free survival [44]. Tolerogenic DC
may exert profound immunosuppressive effects on ef-
fector lymphocytes. Alteration of the IFN-α production by
pDC was recently documented in EOC [44]. Moreover,
through PD-L1/PD-L2 expression, DC can engage the
PD-1 inhibitory pathway, thus inhibiting lymphocyte
proliferation and effector functions [72,73], inducing
tumor-specific T-cell apoptosis [74] and promoting the
differentiation of CD4+ T-cells into Treg [75]. Tolerogenic
DC can also turn-down the immune response through
the induction of IDO activity that inhibits CD8+ T-cell
proliferation [76] and decreases NKG2D expression on
NK-cells [77]. As aforementioned for DC, the tumor
microenvironment also strongly polarizes the macrophage
differentiation and gives rise to TAM [37]. B7-H4+ macro-
phages, a subset of TAM, was shown to suppress TAA-
specific T-cell immunity [60]. An inverse correlation was
evidenced between the intensity of B7-H4 expression on
macrophages in EOC and patient survival [42]. Moreover,
average 5-year survival rate was found significantly higher
in EOC patients with low densities of TAM than in
patients with increased TAM populations [78]. At last,
MDSC are immature myeloid cells with immunosuppres-
sive properties that were evidenced in both mouse model
of EOC and EOC patients [61,79,80]. MDSC exhibit
increased level of arginase-1 (ARG-1) and inductible
Nitric Oxide Synthase (iNOS) activities. Deprivation of L-
Arginine in the tumor microenvironment is emerging as a
key immunosuppressive mechanism. It leads to CD3-zeta
chain downregulation, thereby inhibiting effector T-cell
activation [81]. Increased levels of NO, along with reactive
oxygen and nitrogen species, disrupt signaling through the
IL-2 receptor [82] and alter Ag recognition by nitrating
the TCR [83]. Moreover, MDSC were shown to facilitate
effector T-cell conversion into Treg [84] and to inhibit
intratumoral migration of CD8+ effectors because of the
nitration of CCL2 chemoattractant [85].
Third player in tumor escape is the stromal cell popu-
lation. Overexpression of the endothelin-B receptor by
tumor endothelial cells inhibits concurrent ICAM-1 ex-
pression, thereby impairing the ICAM-1/LFA-1-mediated
transmigration of leukocytes [86]. Overexpression of the
endothelin-B receptor is associated with the absence of
TIL and short survival time in EOC patients [43]. Further-
more, stromal cells may provide chemoattractants for the
immune cells e.g. SDF-1/CXCL12 that recruits pDC [71].
They are also able to secrete soluble immunosuppressive
factors e.g. prostaglandin-E2 (PGE2) which is produced by
mesenchymal stem cells (MSC).
Lavoué et al. Journal of Translational Medicine 2013, 11:147 Page 4 of 12
http://www.translational-medicine.com/content/11/1/147
Finally, the EOC microenvironment is characterized by
the presence of numerous immunosuppressive soluble or
cellular factors (IL-10, TGF-β, PGE2, MIF, HLA-G, IDO,
arginase-1, PD-L1, B7-H4 and Fas-ligand), which can ori-
ginate from various sources, including tumor, immune
and stromal cells [87-91]. PGE2 can be secreted by both
MSC and EOC tumor cells. Of note, overexpression of
COX-2, an inducible enzyme that triggers PGE2 synthesis,
by ovarian tumor cells correlates with resistance to
chemotherapy and poor prognosis [92]. PGE2 inhibits NK
and γδ T-cell cytotoxicity [45,93,94] and induces the dif-
ferentiation of CD4+ T-cells into Treg [95]. Similarly, IDO
is expressed in ovarian tumor cells and tumor-infiltrating
DC [54,55,96]. IDO expression was reported in 43% of an-
alyzed EOC tissues (83/192) [97]. Moreover, its expression
was correlated with worse patient survival [54,55] and
with enhanced peritoneal tumor dissemination [55,98].
IDO is currently thought as one of the main factors that
contribute to tumor-induced immunosuppression by
depleting tryptophan from the microenvironment and
producing tryptophan metabolite kynurenine. Depletion
of tryptophan is sensed by GCN2 kinase pathway driv-
ing effector T-cell anergy and apoptosis [99]. Effects of
kynurenine are mediated by the aryl hydrocarbon receptor
transcription factor that induces increased survival and
motility in cancer cells while favoring Treg expansion and
suppressive effects in effector T-cells [100,101].
Thus, regulatory cells, along with soluble and cellular
immunosuppressive factors, create a tolerogenic micro-
environment in EOC that compromises the antitumoral
immune response [89]. These EOC immunosuppressive
networks characterize the “cancer immunoediting” concept,
which emphasizes a dynamic process of interaction be-
tween cancer and the host immune system [47] (Figure 1).
Modulation of the immune response against EOC with
debulking surgery or chemotherapy
Conventional EOC treatment uses debulking surgery
and systemic chemotherapy. Surgery decreases the
tumor burden and removes poorly vascularized tissues
while cytotoxic drugs eradicate residual tumor cells
[7,102,103]. Little information is available regarding the
impact of surgery on the immunological status in EOC
patients. Major surgery would induce immunosuppres-
sion because of the downregulation of T helper(Th)-1
response [6,104]. However, there is some evidence that
tumor debulking reduces tumor-induced immunosup-
pression in EOC [7,105]. Napoletano et al. demonstrated
that surgery significantly decreases the proportions of
Treg and naive CD4+ T-cells while significantly increas-
ing the ratio of CD8+ T-cells/Treg and the proportions
of effector T-cells among the peripheral blood mono-
nuclear cells [7]. Moreover, surgery significantly increases
IFN-γ secretion by peripheral CD8+ T-cells and reduces
the IL-10 immunosuppressive factor concentration in the
serum [7]. Thus, cancer immunosuppression is partially
reversible, and acquired immunity is enhanced by tumor
debulking surgery in EOC [7].
Regarding chemotherapy, the frequent induction of
lymphopenia suggests that this treatment may be im-
munosuppressive. However, recent data indicate that im-
munity plays a major role in the therapeutic mechanisms
associated with chemotherapy [106,107]. Accordingly, in
advanced-EOC patients treated with platinum-based
chemotherapy, an optimal tumor debulking outcome was
more frequent when CD3+ TIL are present [21]. In
addition, paclitaxel or cisplatin used in EOC cause the
upregulation of mannose-6-phosphate receptor expres-
sion on murine tumor cells. This upregulation sensitizes
tumor cells to granzyme-B protease released by cyto-
toxic T-lymphocytes [108]. Paclitaxel can also stimulate
the proliferation of T-cells and enhance the cytolytic ac-
tivity of NK-cells in models of breast cancer [106,109].
Moreover, in advanced EOC, successful chemotherapy
was shown to be associated with improved functions and
increased proportions of CD8+ effector T-cells [7,8]. Fur-
thermore, chemotherapy decreases immunosuppression
by reducing the number of circulating Treg observed after
neoadjuvant chemotherapy in EOC [7]. Some antitumor
agents can also trigger immunogenic tumor cell death,
causing the cancer cells to expose or secrete immunogenic
signals that trigger an anticancer immune response. Of
note, not all types of chemotherapy, but oxaliplatin and
3/25 tested anthracyclines, elicit immunogenic cell
death [110-112]. Altogether, these data provide evidence
that debulking surgery and chemotherapy may restore,
by direct and indirect effects, the equilibrium phase or
the elimination phase in tumors that escaped initial
immunosurveillance [106].
Immunotherapy in EOC: how to counteract
immunosuppression?
Preclinical and preliminary clinical studies aimed at prov-
ing the immunotherapy concept in EOC were initiated
by using monoclonal Ab (mAb), vaccinations or adoptive
T-cell transferts [113-115]. The majority of these studies
were uncontrolled phase I/II studies, with small sample
sizes and heterogeneous inclusion criteria (recurrent or
chemotherapy-refractory diseases) disrupting the compari-
sons and the identification of the best strategy.
Several mAb targeting TAA were tested in EOC [116]:
anti-CA125 oregovomab and abagovomab [117-119]; anti-
HER-2/neu trastuzumab and pertuzumab [10,120]; anti-
FR-α farletuzumab α [121], anti-EpCAM catumaxomab
[122] and anti-Tag72 B72.3 [123]. All these mAb dem-
onstrated adequate safety and tolerability but failed to
demonstrate clear clinical benefits, even when an im-
munological response was evidenced [114,115]. Active
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immunotherapy by vaccination based on peptides or
cellular approaches were also evaluated. Clinically tested
peptides include NY-ESO-1 [124,125], p53 [126], HER2-
neu [127] and multiple constructed-peptides (HER2-neu/
MAGE-A1/FRα [128] and MUC-1/carcinoembryonic anti-
gen [129]). In addition, cell vaccines include DC pulsed
with ARNm (FRα [130]), peptides (HER2-neu, MUC1
[131]), autologous tumor Ag [132] or whole tumor cell
lysate [133]. Vaccine therapies were well tolerated and
demonstrated immunological responses, but provided only
minor clinical benefits. Of note, these studies enrolled low
numbers of patients and have generally not yet evolved
past phase I/II studies. A third immunotherapy strategy is
adoptive T-cell therapy, which uses cytotoxic lymphocytes
with natural or engineered reactivity against cancer cells.
Cytotoxic lymphocytes are generated in vitro and then
transferred back into the patient to elicit cytotoxic re-
sponses against the patient’s own tumor cells. Only five
phase I/II EOC studies, which enrolled few patients (<20),
are available [134-138]. They used either TIL or peripheral
autologous T-cells and were well tolerated; unfortunately,
only modest clinical benefits were demonstrated. Thus,
to date, results of these trials are disappointing, regard-
less of the strategy [115]. However, these trials may
suffer from some pitfalls. First, they often enrolled
patients with recurrent or refractory-chemotherapy
diseases, i.e. patients at terminal stages of the disease,
with strong immunodepression. It is likely that enroll-
ment of patients at earlier stages of disease could be
more successful. Secondly, all these trials focused on
the recognition and killing of tumor cells and
neglected to consider the immunosuppressive impact
of the tumor microenvironment. Thus, improvement
of theses immunotherapies is needed. For example,
chimeric antigen receptor(CAR)-modified T cell ther-
apy is highly promising [139,140]. CAR T-cells could
be engineered to only express the downstream pathway
of activating receptors. This refined adoptive therapy
skips inhibitory signals expressed by the tumor envir-
onment. In addition, use of adjuvant drugs targeting
immunosuppressive cells or soluble/cellular immuno-
modulatory factors could be the key to fully unleash
the potential of immunotherapy by breaking peripheral
tolerance.
Below, we review some immunomodulatory tools
already in clinical use or likely to be assessed in the near
future, that interact with the immunosuppressive factors
found in the EOC microenvironment.
First approach may consist in depleting the host of the
regulatory cells or in limiting their recruitment within
the tumor. Treg depletion may be achieved using low-
dose cyclophosphamide which prevents, under incom-
pletely understood mechanism, Treg development and
functionality [141,142]. An alternative strategy uses the
expression by Treg of the IL-2 receptor alpha (CD25).
Recombinant fusion protein of IL-2 and diphtheria toxin
(OntakW, Eisai) was tested in EOC patients and showed
effective depletion of circulating Treg [143]. Moreover,
in patients with metastatic breast cancer, the anti-CD25
mAb daclizumab (ZenapaxW, Roche) demonstrated se-
lective T-lymphocyte killing properties, allowing Treg
depletion for several weeks [144]. However, it is unclear
if Treg depletion occurs at EOC locations (solid tumor,
malignant ascites) and results in tumor regression
[143-145]. Moreover, as effector cells also express
CD25, anti-CD25 mAb may also induce unwanted de-
pletion of effector cells [146]. In addition, blocking the
ICOS-pathway could inhibit the pDC-triggered prolif-
eration of Treg within the tumor [64]. However, as
ICOS pathway also favors the differentiation of T
helper(Th)-17 cells which might either promote tumor
growth or antitumor response [35,37,147-150] careful
preclinical investigations of ICOS inhibitors (314.8
mAb) is needed [63].
The role of chemoattractants in the recruitment of
immune cells also gives a great opportunity to reduce
the infiltration of regulatory cells within the tumor
[151]. First candidates are under investigation. CCR4
antagonists were shown to block the recruitment of Treg
instructed by CCL22 and CCL17 and to favor the induc-
tion of antigen-specific CD8+ T cell response after vac-
cination [152]. Similarly, BindaritW that inhibits CCL2
synthesis and therefore restricts the recruitment in the
tumor of immature myeloid cells, was shown to induce
tumor regression in prostate and breast cancer animal
models [153]. Regulatory cell depletion could also be
achieved by improving the maturation of immature
myeloid cells [154] using all trans retinoic acid [155] or
ultra-low non-cytotoxic doses of paclitaxel (chemo-
immunomodulation) [156].
Another attractive approach is the use of either antag-
onists of immune-repressor molecules or agonists of
immune-activating receptors [157]. Checkpoint blockade
receptors comprise CTLA-4, PD-1 and NK inhibitory
receptors (KIR) that, upon engagement, dampen the im-
mune response. CTLA-4 predominantly regulates T-cells
at the priming phase of activation by competing with
CD28+ for binding of B7-1 and B7-2 on DC. CTLA-4
engagement prevents T-cells from achieving full activa-
tion. Accordingly, anti-CTLA-4 mAb were shown to
activate CD4+ and CD8+ effector T-cells both directly by
removing inhibitory checkpoints and indirectly via the
inhibition of regulatory T-cell activity [158]. Eleven EOC
patients, previously vaccinated with GM-CSF and irradi-
ated autologous tumor cells, received anti-CTLA-4
ipilimumab (YervoyW, Bristol-Myers-Squibb, BMS). Sig-
nificant antitumor effects were observed in a minority of
these patients and were correlated with increased CD8+
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T-cells/Treg ratio [159]. In contrast to CTLA-4, PD-1 sig-
naling occurs in the tumor, where PD-L1-expressing
tumor cells can signal through PD-1 on TIL to turn-down
the antitumor T-cell response. In EOC, the PD-1/PD-L1
pathway seems to be a dominant immunosuppression
mechanism [73]. PD-L1 expression in EOC was demon-
strated to be an independent unfavorable prognostic factor
and to promote peritoneal dissemination [24,160]. Several
PD-1/PD-L1-pathway blocking agents were assessed in
various cancer types and promising results were recently
reported. Nivolumab (BMS-936558, Bristol-Myers-Squibb)
was tested in 296 patients most harboring lung cancer,
renal cell cancer and melanoma, with clinical benefits ap-
parent in 20 to 25% of the patients [161]. Impressive dur-
able responses were reported. 25/42 patients with PD-L1
-positive tumor experienced an objective response while
none of the 17/42 PD-L1-negative patients did. However,
lack of prognostic association was reported elsewhere and
the usefulness of PD-L1 as a biomarker need to be ex-
plored in larger prospective studies [162]. In addition,
Bramher and colleagues reported that 1/17 EOC patients
treated with anti-PD-L1 mAb (BMS-936559) experienced
an objective response [163]. New trials enrolling patients
with solid tumor of multiple origins are underway and
informative data in EOC are expected [164]. Inhibition of
the cytotoxic properties of NK-cells through KIR engage-
ment may also contribute to the tumor escape. Some anti-
KIR antibodies, such as lilirumab (Bristol-Myers-Squibb),
recently entered clinical development phases. First data
were obtained in hematological diseases and phase I stud-
ies recruiting patients with solid tumors are ongoing
[165,166]. As a corollary, agonistic agents of costimulatory
molecules such as glucocorticoid-induced TNFR (GITR),
OX40, CD137 are candidates to boost the antitumor
immune response. A dose-escalation phase I clinical trial
(NCT01239134) with agonist anti-GITR mAb (TRX518)
was recently initiated.
Third possibility is to repress the activity of enzymes
(IDO, ARG-1, iNOS) that were shown to inhibit the im-
mune response. Data from first clinical trials using IDO
inhibitors, notably the isomers of 1-methyl-tryptophan
(1MT), were disappointing, but these studies may suffer
from lack of potent and selective IDO inhibitors. New
compounds recently entered clinical trials [167]. A phase
II study of IDO inhibitor INCB024360 is currently
recruiting patients with biochemical-recurrent-only EOC
following complete remission with first-line chemotherapy
(clinical trial: NCT01685255). In addition, inhibitors of
phosphodiesterase(PDE)-5, e.g. sildenafil, were reported to
increase intracellular concentrations of cGPM, resulting in
the inhibition of both ARG-1 and iNOS. PDE-5 inhibitors
along with nitroaspirin or specific ARG-1/iNOS inhibitors
might provide new therapeutic strategy to recover potent
antitumor immune response [154].
Lastly, PGE2 was shown to be a crucial immunosup-
pressive factor in EOC, as it impairs the cytotoxic proper-
ties of effector cells such as Vγ9Vδ2T-cells [45] and also
induces the differentiation of MDSC from bone marrow
stem cells in a mouse model [168]. PGE2 biosynthesis is
regulated by the inducible COX-2 enzyme and could be
inhibited by the COX-2-specific inhibitor celecoxib
(CelebrexW, Pfizer). In a mouse model, celecoxib prevented
the local and systemic expansion of MDSC, impaired the
suppressive function of these cells, and significantly im-
proved vaccine immunotherapy [169]. Thus, celecoxib,
currently used in the prevention of colorectal adenoma-
tous polyps [170], could be tested in combination with
immunotherapy to reduce the immunosuppression by
MDSC in EOC. Another possible strategy to counteract
the immunosuppressive influence of PGE2 on Vγ9Vδ2T
cells could be to restore the cytotoxic properties of these
cells with a zoledronate perfusion [45]. In addition,
zoledronate was shown to prevent the immunosuppressive
polarization of TAM [171,172] which is a major compo-
nent of the leukocyte infiltrate in the tumor microenvir-
onment and plays a dominant role in the production of
immune suppressive cytokines in EOC [60]. Thus,
zoledronate, which is currently used for the manage-
ment of osteoporosis and bone metastasis, appears to be
an attractive molecule to reinforce the immune re-
sponse. Altogether, these data warrant further explor-
ation of combinatorial therapies with immunotherapy
and bisphosphonates.
In conclusion, accumulated evidences support the
immunoediting hypothesis and the idea that EOC is im-
munogenic. Immunotherapeutic protocols aimed at modu-
lating the immune system to strengthen the spontaneous
antitumor immune response are under investigation.
Targeting the immunosuppressive mechanisms could be
the key to fully unleash the potential of immunotherapy.
The combination of molecules endowed with immuno-
modulatory properties with immunotherapy targeting the
tumor cells will hopefully increase the survival of EOC
patients. Careful preclinical evaluation will be necessary to
screen optimal combinations before clinical trials.
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